SynthesisCirculation2025
Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
Synthesis in Circulation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04363697. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients Who Have Been Stabilized During Hospitalization for Acute Heart Failure DAPAgliflozin and Effect on Cardiovascular Events in ACuTe Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- "In-Hospital Initiation of SGLT-2 Inhibitors in Acute Heart Failure: A Systematic Review and Meta-Analysis of Clinical, Decongestion, and Safety Outcomes".Cardiovascular drugs and therapy · 2026Pooled it
- Impact of SGLT2 Inhibitors on Mortality Across Different Populations: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2026Pooled it
- Cost of Chronic Heart Failure Among Adult Europeans-A Systematic Literature Review.PharmacoEconomics - open · 2026Pooled it
- SGLT2 inhibitors: mechanisms, physiology and pharmacology, and clinical applications.Molecular biomedicine · 2026Review
- Update on clinical heart failure trials.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Review
- Advances in Clinical Cardiology 2025: A Summary of Key Clinical Trials.Advances in therapy · 2026Review
- Review
- HLM Staging and Treatment Benefit of SGLT2i Across Heart Failure Severity.Journal of cardiovascular development and disease · 2026Article
- Molecular Basis of Adipose-Cardiac Crosstalk in Cardiovascular Diseases: From Mechanisms to Therapeutic Opportunities.Biomolecules · 2026Review
- Cardioprotective properties of empagliflozin and other SGLT2 inhibitors.Nature reviews. Cardiology · 2026Review
- Exploration of the Pathogenesis and Treatment of Heart Failure.Reviews in cardiovascular medicine · 2026Review
- Clinical Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors Among Older Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.Journal of the American Heart Association · 2026Article
- Cardiovascular pharmacotherapy in 2025.European heart journal. Cardiovascular pharmacotherapy · 2026Review
- Heart failure in 2025: new insights, therapies, and clinical directions.Journal of thoracic disease · 2026Review
- Article
- SOCS1 Mimetic Peptide Enhances Empagliflozin Improvement on Kidney Damage in the Type 2 Diabetes Mouse Model BTBR ob/ob.International journal of molecular sciences · 2026Article
- Real-world data on early initiation of sodium-glucose co-transporter-2 inhibitors in newly diagnosed heart failure with reduced ejection fraction.ESC heart failure · 2026Article
- Durable Remission After Triple Therapy in New-Onset HFrEF: Implications for a Strategy of "Personalized GDMT".JACC. Case reports · 2026Article
- Research Progress of SGLT2 Inhibitors in the Treatment of Acute Heart Failure: A Narrative Review.International journal of general medicine · 2026Review
- Early Sodium-Glucose Cotransporter 2 Inhibitor Initiation During Hospitalisation: Viewpoint on the DAPA ACT HF-TIMI 68 Trial.European cardiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors.
Funding
Abstract
backgroundSGLT2 (sodium-glucose cotransporter-2) inhibitors reduce the risk of cardiovascular death or worsening heart failure (HF) in outpatients with HF. Data on initiation in patients hospitalized for HF are limited.
methodsWe conducted a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of in-hospital initiation of dapagliflozin (10 mg daily) in patients hospitalized for HF. The primary efficacy outcome was a composite of time to cardiovascular death or worsening HF through 2 months. Key safety outcomes included symptomatic hypotension and worsening kidney function. A prespecified meta-analysis of randomized trials evaluating initiation of SGLT2 inhibitors in patients hospitalized for HF was performed.
resultsOf 2401 patients (median age, 69 [Q1-Q3, 58-77] years, 815 [33.9%] women, 448 [18.7%] Black race, 1717 [71.5%] left ventricular ejection fraction ≤40%, 1074 [44.7%] newly diagnosed HF) randomized between September 2020 and March 2025, 1218 were assigned to dapagliflozin and 1183 to placebo. The primary outcome occurred in 133 patients (10.9%) in the dapagliflozin group and 150 (12.7%) in the placebo group (hazard ratio [HR], 0.86 [95% CI, 0.68-1.08];
conclusionsIn this trial, in-hospital initiation of dapagliflozin did not significantly reduce the risk of cardiovascular death or worsening HF through 2 months in hospitalized HF patients. However, the totality of randomized clinical trial data suggests that in-hospital initiation of SGLT2 inhibitors may reduce the early risk of cardiovascular death or worsening HF and of all-cause mortality. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04363697.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.